Johnson & Johnson has announced robust second-quarter financial results for 2026, exceeding market expectations for both revenue and profit. The healthcare giant reported revenue of $25.31 billion, surpassing the consensus estimate of $25.02 billion and marking a 6.6% increase from the same period last year. Adjusted earnings per share also came in strong at $2.90, beating analysts' projections of $2.86.
Buoyed by this performance, Johnson & Johnson has raised its full-year 2026 guidance. The company now anticipates adjusted earnings per share to be between $11.60 and $11.75, with a midpoint of approximately $11.68. Full-year revenue projections have also been revised upwards, with an expected range of $100.8 billion to $101.4 billion, centering around $101.1 billion. This increased outlook signals management's continued optimism regarding the company's business trajectory.
The company's strong performance was driven by its key segments, including Innovative Medicine and MedTech. Growth in areas like oncology and neuroscience, with key drugs such as Darzalex and Tremfya, has been a significant contributor. However, the company continues to navigate headwinds from patent expirations affecting older products like Stelara.
Despite the positive financial report and raised guidance, Johnson & Johnson's shares saw a decrease in pre-market trading. This movement against the trend of positive results highlights the market's complex reactions to earnings announcements, even when fundamental performance is strong. Year-to-date, however, J&J's stock has demonstrated resilience, with a gain of approximately 22%, outperforming the S&P Global 100 Index.
